Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
Author:
Publisher
MDPI AG
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Link
http://www.mdpi.com/1424-8247/10/2/40/pdf
Reference207 articles.
1. Improved survival in multiple myeloma and the impact of novel therapies
2. Novel Generation of Agents With Proven Clinical Activity in Multiple Myeloma
3. From the bench to the bedside: emerging new treatments in multiple myeloma
4. Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade
5. Proteasome inhibitors: antitumor effects and beyond
Cited by 39 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. NCX1/Ca2+ promotes autophagy and decreases bortezomib activity in multiple myeloma through non-canonical NFκB signaling pathway;Cell Communication and Signaling;2024-05-06
2. Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives;Experimental Hematology & Oncology;2024-04-23
3. Histone deacetylase (HDAC) inhibitor specificity determinants are preserved in a class of dual HDAC/non-covalent proteasome inhibitors;Bioorganic & Medicinal Chemistry;2024-04
4. Treatment of multiple myeloma: What is the impact on T-cell function?;Therapeutic Advances in Hematology;2024-01
5. The role of proteasomes in tumorigenesis;Genes & Diseases;2023-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3